Beauty
Health
Lifestyle
Medicine
Biowatch
Column
Kormedi.com TV
Notice
Newsletter subscription
Beauty
Health
Lifestyle
Medicine
Biowatch
Column
Kormedi.com TV
Notice
Languages
ENGLISH
English (US)
ASIAN
Монгол
日本語
Tiếng Việt
Bahasa Indonesia
中文 (简体, 中国大陆)
EUROPEAN
Русский
Español (España)
Français (France)
MIDDLE_EAST_AFRICA
العربية
Search results for "Celltrion"
Home
Celltrion Secures Historic FDA Interchangeability Status for Truxima
Celltrion announced on the 1st that the U.S. Food and Drug Administration has granted interchangeable status to Truxima (active ingredient:...
07/06/2026, 03:44 ET
Celltrion Advances Next-Generation Immuno-Oncology Candidate with Strong Preclinical Results
Celltrion has announced promising preclinical data for its investigational immuno-oncology candidate, CT-P72/ABP-102, demonstrating potent antitumor...
06/15/2026, 09:10 ET
Celltrion to Acquire French Healthcare Specialist Gifrer, Eyeing European Pharmacy Market
Celltrion announced on the 12th its acquisition of Gifrer, a French healthcare specialist with a 114-year history.
05/14/2026, 01:07 ET
A Milestone for K-Bio: Celltrion’s Truxima Surpasses Global Blockbuster Rituxan in U.S. Prescriptions
Truxima , a blood cancer treatment developed by Celltrion, has become the first Korean-made biosimilar to rank number...
04/09/2026, 01:13 ET
Celltrion Secures Japanese Approval for Xolair and Eylea Biosimilars
Celltrion announced on the 27th that it has obtained marketing authorization from Japan’s Ministry of Health, Labour...
03/30/2026, 02:30 ET
Celltrion to Double Production Capacity with 1.2 Trillion Won Investment
Celltrion has announced a massive expansion across three of its major facilities in South Korea and the United States,...
03/30/2026, 02:17 ET
Celltrion Secures Canadian Approval for ‘Steqeyma’ Autoinjector Formulation
Celltrion announced on March 20, 2026, that it has received additional approval from Health Canada for the autoinjector...
03/23/2026, 02:59 ET
Celltrion: “Zymfentra prescriptions surging in the U.S.… growth is accelerating in earnest”
Celltrion’s subcutaneous formulation for autoimmune diseases, “Zymfentra,” which launched in the United States, has...
03/18/2026, 03:08 ET
Launch of 'TrumpRX' Sells Drugs at Steep Discounts: Will Celltrion and Samsung Biologics Face Price Pressure?
The prescription drug sales platform 'TrumpRX', named after U. S. President Donald Trump, has officially launched.
02/09/2026, 04:32 ET
Celltrion "Asthma Drug 'Omrilclo' Captures 60% Market Share in Spain"
Celltrion announced on the 4th that its chronic spontaneous urticaria and allergic asthma treatment, 'Omrilclo ', is...
02/05/2026, 04:06 ET
Previous
1
2
3
Next